Advertisement

What is appropriate target delineation for MRI-based brachytherapy for medically inoperable endometrial cancer?

Published:November 03, 2022DOI:https://doi.org/10.1016/j.brachy.2022.10.001

      Abstract

      PURPOSE

      For medically inoperable endometrial cancer (MIEC), the volumetric target of image-guided brachytherapy (IGBT) techniques is not well established. We propose a high-risk CTV (HRCTV) concept and report associated rates of local control and toxicity.

      METHODS AND MATERIALS

      For all MIEC patients receiving definitive external beam radiotherapy (EBRT) followed by MRI-based IGBT at a single institution, BT dose was prescribed to HRCTV defined as GTV plus endometrial cavity with a planning goal of a summed EQD2 D90 of ≥85 Gy. Freedom from local progression (FFLP) and overall survival (OS) were estimated via Kaplan Meier method.

      RESULTS

      Thirty two MIEC patients received EBRT followed by MRI-based IGBT between December 2015 and August 2020. Median follow up was 19.8 months. A total of 75% of patients had FIGO stage I/II disease, 56% endometrioid histology, and 50% grade 3 disease. OS was 73.6% (95% CI 57.8%–89.3%) at 12 months and 65.8% (95% CI 48.4%–83.2%) at 24 months. FFLP was 93.8% (95% CI 85.3%–100%) at 12 months and 88.8% (95% CI 86.6%–91.0%) at 24 months. 23 (72%) patients experienced no RT-related toxicity, while 2 of 32 patients (6%) experienced late grade 3+ toxicities (grade 3 refractory vomiting; grade 5 GI bleed secondary to RT-induced proctitis).

      CONCLUSIONS

      Patients with MIEC receiving definitive EBRT followed by MRI-based IGBT prescribed to the MRI-defined HRCTV demonstrated favorable long-term local control with an acceptable toxicity profile.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Brachytherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel RL
        • Miller KD
        • Fuchs HE
        • Jemal A.
        Cancer statistics, 2022.
        CA Cancer J Clin. 2022; 72: 7-33
        • Ertel M
        • Staley SA
        • Nguyen T
        • et al.
        Contemporary incidence of medical inoperability in clinical stage I endometrial cancer.
        Ann Surg Oncol. 2021; 28: 8987-8995
        • Podzielinski I
        • Randall ME
        • Breheny PJ
        • et al.
        Primary radiation therapy for medically inoperable patients with clinical stage I and II endometrial carcinoma.
        Gynecol Oncol. 2012; 124: 36-41
        • Wegner RE
        • Beriwal S
        • Heron DE
        • et al.
        Definitive radiation therapy for endometrial cancer in medically inoperable elderly patients.
        Brachytherapy. 2010; 9: 260-265
        • Inciura A
        • Atkocius V
        • Juozaityte E
        • Vaitkiene D.
        Long-term results of high-dose-rate brachytherapy and external-beam radiotherapy in the primary treatment of endometrial cancer.
        J Radiat Res. 2010; 51: 675-681
        • Kupelian PA
        • Eifel PJ
        • Tornos C
        • et al.
        Treatment of endometrial carcinoma with radiation therapy alone.
        Int J Radiat Oncol Biol Phys. 1993; 27: 817-824
        • Nguyen C
        • Souhami L
        • Roman TN
        • Clark BG.
        High-dose-rate brachytherapy as the primary treatment of medically inoperable stage I–II endometrial carcinoma.
        Gynecol Oncol. 1995; 59: 370-375
        • Churn M
        • Jones B.
        Primary radiotherapy for carcinoma of the endometrium using external beam radiotherapy and single line source brachytherapy.
        Clin Oncol. 1999; 11: 255-262
        • Niazi TM
        • Souhami L
        • Portelance L
        • et al.
        Long-term results of high-dose-rate brachytherapy in the primary treatment of medically inoperable stage I–II endometrial carcinoma.
        Int J Radiat Oncol Biol Phys. 2005; 63: 1108-1113
        • Coon D
        • Beriwal S
        • Heron DE
        • et al.
        High-dose-rate Rotte “Y” applicator brachytherapy for definitive treatment of medically inoperable endometrial cancer: 10-Year results.
        Int J Radiat Oncol Biol Phys. 2008; 71: 779-783
        • Dutta SW
        • Trifiletti DM
        • Grover S
        • et al.
        Management of elderly patients with early-stage medically inoperable endometrial cancer: Systematic review and National Cancer Database analysis.
        Brachytherapy. 2017; 16: 526-533
        • Viswanathan AN
        • Creutzberg CL
        • Craighead P
        • et al.
        International brachytherapy practice patterns: A survey of the Gynecologic Cancer Intergroup (GCIG).
        Int J Radiat Oncol Biol Phys. 2012; 82: 250-255
        • Gill BS
        • Chapman BV
        • Hansen KJ
        • et al.
        Primary radiotherapy for nonsurgically managed Stage I endometrial cancer: Utilization and impact of brachytherapy.
        Brachytherapy. 2015; 14: 373-379
        • Schwarz JK
        • Beriwal S
        • Esthappan J
        • et al.
        Consensus statement for brachytherapy for the treatment of medically inoperable endometrial cancer.
        Brachytherapy. 2015; 14: 587-599
        • Weitmann HD
        • Pötter R
        • Waldhäusl C
        • et al.
        Pilot study in the treatment of endometrial carcinoma with 3D image–based high-dose-rate brachytherapy using modified Heyman packing: Clinical experience and dose–volume histogram analysis.
        Int J Radiat Oncol Biol Phys. 2005; 62: 468-478
        • Ohkubo Y
        • Kato S
        • Kiyohara H
        • et al.
        Dose volume analysis of radiotherapy for inoperable patients with stage I-II endometrial carcinoma.
        J Radiat Res. 2011; 52: 666-673
        • Beriwal S
        • Kim H
        • Heron DE
        • Selvaraj R.
        Comparison of 2D vs. 3D dosimetry for Rotte “Y” applicator high dose rate brachytherapy for medically inoperable endometrial cancer.
        Tech Cancer Res Treatment. 2006; 5: 521-527https://doi.org/10.1177/153303460600500509
        • Manea E
        • Escande A
        • Bockel S
        • et al.
        Risk of late urinary complications following image guided adaptive brachytherapy for locally advanced cervical cancer: Refining bladder dose-volume parameters.
        Int J Radiat Oncol Biol Phys. 2018; 101: 411-420
        • Kirchheiner K
        • Nout RA
        • Lindegaard JC
        • et al.
        Dose–effect relationship and risk factors for vaginal stenosis after definitive radio(chemo)therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study.
        Radiother Oncol. 2016; 118: 160-166
        • Mazeron R
        • Fokdal LU
        • Kirchheiner K
        • et al.
        Dose–volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: Results from the prospective multicenter EMBRACE study.
        Radiother Oncol. 2016; 120: 412-419
        • Fowler JF.
        The linear-quadratic formula and progress in fractionated radiotherapy.
        Br J Radiol. 1989; 62: 679-694
        • Susko M
        • Craciunescu O
        • Meltsner S
        • et al.
        Vaginal dose is associated with toxicity in image guided tandem ring or ovoid-based brachytherapy.
        Int J Radiat Oncol Biol Phys. 2016; 94: 1099-1105
        • Haie-Meder C
        • Pötter R
        • Van Limbergen E
        • et al.
        Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): Concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV.
        Radiother Oncol. 2005; 74: 235-245
        • Gebhardt B
        • Gill B
        • Glaser S
        • et al.
        Image-guided tandem and cylinder brachytherapy as monotherapy for definitive treatment of inoperable endometrial carcinoma.
        Gynecol Oncol. 2017; 147: 302-308
        • Acharya S
        • Esthappan J
        • Badiyan S
        • et al.
        Medically inoperable endometrial cancer in patients with a high body mass index (BMI): Patterns of failure after 3-D image-based high dose rate (HDR) brachytherapy.
        Radiother Oncol. 2016; 118: 167-172
        • Jordan SE
        • Micaily I
        • Hernandez E
        • et al.
        Image-guided high-dose-rate intracavitary brachytherapy in the treatment of medically inoperable early-stage endometrioid type endometrial adenocarcinoma.
        Brachytherapy. 2017; 16: 1144-1151
        • Yaney A
        • Healy E
        • Wald P
        • et al.
        Toxicity and outcomes associated with high-dose rate brachytherapy for medically inoperable endometrial cancer.
        Brachytherapy. 2021; 20: 368-375
        • Espenel S
        • Kissel M
        • Garcia MA
        • et al.
        Implementation of image-guided brachytherapy as part of non-surgical treatment in inoperable endometrial cancer patients.
        Gynecol Oncol. 2020; 158: 323-330
        • Mutyala S
        • Patel G
        • Rivera AC
        • et al.
        High dose rate brachytherapy for inoperable endometrial cancer: A case series and systematic review of the literature.
        Clin Oncol. 2021; 33: e393-e402
        • Draghini L
        • Maranzano E
        • Casale M
        • et al.
        Definitive three-dimensional high-dose-rate brachytherapy for inoperable endometrial cancer.
        J Contemp Brachyther. 2017; 9: 118-123